Summit Therapeutics Inc.

SMMT · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders80.9%

Institutions17.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	$0	$0	$705000	$1.81M	$860000
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	–	-$226.00M	-$609.65M	-$72.09M	-$86.19M	-$53.19M
Operating income as a percentage of revenue.	–	–	–	-10225.4%	-4764.3%	-6185.2%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$1.08B	-$221.31M	-$614.93M	-$78.78M	-$88.60M	-$52.70M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.44	$-0.31	$-0.99	$-0.41	$-0.96	$-0.76
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.44	$-0.31	$-0.99	$-0.41	$-0.96	$-0.76

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$225.27M	$104.86M	$71.42M	$348.61M	–	$66.40M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$751.18M	$435.56M	$202.95M	$664.17M	$113.37M	$102.50M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$0	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$92.32M	$46.81M	$125.26M	$537.51M	$30.09M	$23.05M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$658.86M	$388.75M	$77.69M	$126.65M	$83.28M	$79.45M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$322.93M	-$142.11M	-$76.76M	-$41.58M	-$72.59M	-$48.10M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$657000	$139000	$128000	$624000	$306000	$421000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$323.59M	-$142.25M	-$76.89M	-$42.21M	-$72.89M	-$48.52M

	You	Peer avg
P/E	–	19.7
Revenue Growth	–	+42.1%
ROE	-192.5%	28.6%

Summit Therapeutics Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison